logo-loader
viewOpen Orphan PLC

Open Orphan PLC - Result of AGM

RNS Number : 7861T
Open Orphan PLC
22 July 2020
 

22 July 2020

Open Orphan plc

("Open Orphan" or the "Company")

Result of AGM

 

Open Orphan plc (ORPH), a rapidly growing specialist CRO pharmaceutical services company which is the world leader in the testing of vaccines and antivirals using human challenge clinical trials is pleased to announce that at the Company's Annual General Meeting held today, all resolutions put to the meeting were duly passed.

 

For further information please contact

  Open Orphan plc

+353 (0)1 644 0007

  Cathal Friel, Executive Chairman

 

 

 

  Arden Partners plc (Nominated Adviser and Joint Broker)

+44 (0)20 7614 5900

  John Llewellyn-Lloyd / Benjamin Cryer / Dan Gee-Summons

 

 

 

  finnCap plc (Joint Broker)

+44 (0) 20 7220 500

  Geoff Nash / James Thompson/ Richard Chambers

 

 

 

  Davy (Euronext Growth Adviser and Joint Broker)

+353 (0)1 679 6363

  Anthony Farrell

 

 

 

  Camarco (Financial PR)

+44 (0)20 3757 4980

 Tom Huddart / Hugo Liddy

 

 

Notes to Editors - Open Orphan:

Open Orphan is a rapidly growing niche CRO pharmaceutical services company which is a world leader in the testing of vaccines and antivirals through the use of human challenge clinical trials. Conducted from Europe's only 24-bedroom quarantine clinic with onsite virology providing individually isolated rooms and connected to our specialist laboratory facility. Which offers highly specialised virology and immunology laboratory services to support pre-clinical and clinical respiratory drug, antiviral, and vaccine discovery and development.  Reliable laboratory analysis underpinned by scientific expertise is essential when processing and analysing clinical samples. Robust quality processes support our team of scientists in the delivery of submission ready data.

The Company has a leading portfolio of 8 viral challenge study models which are: 2 FLU, 2 RSV, 1 HRV, 1 Asthma, 1 cough and 1 COPD viral challenge models. As announced in early March, Open Orphan is rapidly advancing a number of Coronavirus challenge study models and expects to be helping many COVID-19 vaccine development companies to test their vaccines. No other company in the world has such a portfolio, with only two competitors globally having 1 challenge study model each.    In June 2020  hVIVO COVID Clear Test  was launched, the most accurate antibody test available to UK employers, helping them to get their people back to work.

Open Orphan comprises of two commercial specialist CRO services businesses ( hVIVO  and  Venn ) and is developing an early stage orphan drug genomics data platform business. This platform captures valuable genetic data from patient populations with specific diseases with designated orphan drug status and incorporating AI tools. In June 2019, Open Orphan acquired AIM-listed Venn Life Sciences Holdings plc in a reverse take-over and in January 2020 it completed the merger with hVIVO plc. Venn, as an integrated drug development consultancy, offers CMC (chemistry, manufacturing and controls), preclinical, Phase I & II clinical trials design and execution. The merger with hVIVO created a European full pharma services company broadening the Company's customer base and with complementary specialist CRO services, widened the range of the Company's service offerings.


 

 


This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [email protected] or visit www.rns.com.
 
END
 
 
RAGPPUBWMUPUGGP

Quick facts: Open Orphan PLC

Price: 15.25

Market: AIM
Market Cap: £101.51 m
Follow

Create your account: sign up and get ahead on news and events

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

FOR OUR FULL DISCLAIMER CLICK HERE

Watch

Open Orphan PLC: Proactive One2One Virtual Conference

Open Orphan PLC's (LON:ORPH) Cathal Friel presents at the Proactive One2One Virtual Conference. The company's a rapidly growing specialist CRO pharmaceutical services company which is a world leader in the testing of vaccines and antivirals through the use of human challenge clinical trials. It...

3 weeks, 1 day ago